Prior to joining Addex, Dr Galibert was senior staff scientist at Merck Serono. From 1996 to 2005 he held successive research positions at Immunex (acquired by Amgen) and Amgen, where he cloned the receptor activator of nuclear factor kappa B ligand (RANKL) and co-authored the initial patent leading to the development of Amgen’s denosumab, a monoclonal antibody against RANKL, which is in Phase III development for postmenopausal osteoporosis and in clinical development for other indications.
Vincent Mutel, CEO of Addex Pharmaceuticals, said: “I am confident that Dr Galibert’s expertise and leadership in inflammation and immunology will attract an exciting team of experienced inflammation researchers to Addex.”